✦ LIBER ✦

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

✍ Scribed by Gough, Stephen C L; Bode, Bruce; Woo, Vincent; Rodbard, Helena W; Linjawi, Sultan; Poulsen, Pernille; Damgaard, Lars H; Buse, John B

Book ID: 126171040
Publisher: Elsevier
Year: 2014
Tongue: English
Weight: 284 KB
Volume: 2
Category: Article
ISSN: 2213-8587
DOI: 10.1016/S2213-8587(14)70174-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of a fixed-ratio com

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

✍ Gough, Stephen C L; Bode, Bruce; Woo, Vincent; Rodbard, Helena W; Linjawi, Sulta 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 284 KB

## Background: A fixed-ratio combination of the basal insulin analogue insulin degludec and the glucagon-like peptide-1 (glp-1) analogue liraglutide has been developed as a once-daily injection for the treatment of type 2 diabetes. we aimed to compare combined insulin degludec-liraglutide (ideglira

Efficacy and safety of insulin degludec

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

✍ Zinman, Bernard; DeVries, J Hans; Bode, Bruce; Russell-Jones, David; Leiter, Law 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 337 KB

The Efficacy and Safety of Insulin Deglu

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

✍ Meneghini, L.; Atkin, S. L.; Gough, S. C. L.; Raz, I.; Blonde, L.; Shestakova, M 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 842 KB

Efficacy and Safety Profile of Exenatide

Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study

✍ Inagaki, Nobuya; Atsumi, Yoshihito; Oura, Tomonori; Saito, Hitoshi; Imaoka, Take 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 962 KB